Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.942 USD | +5.45% | +34.37% | +17.28% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.28% | 88.39M | |
+26.51% | 661B | |
+27.49% | 566B | |
-6.35% | 352B | |
+20.41% | 332B | |
+3.48% | 283B | |
+14.38% | 231B | |
+5.26% | 200B | |
-8.96% | 195B | |
-4.87% | 145B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Transcript : HOOKIPA Pharma Inc. - Special Call